Oncoscan analysis in paired samples of primary and recurrent glioblastoma

Introduction

Survival of patients suffering from glioblastoma multiforme is estimated for 12.6 months and survival rate of over 90% these patients is only 5 years. Glioblastoma multiforme is characterized by unprecedented agressivity therefore this disease deserve intense focus of multiple approaches to reveal its molecular nature. Deeper insight into gliomagenesis was allowed due to discovery of new biomarkers over the past few years and these markers also facilitated identification of possible predictive and also prognostic markers. Recent literature highlights a growing occurence of copy number aberrations with prognostic, diagnostic and therapy prediction value. Present suggestions outlines that copy number may have more significant impact than somatic mutations to guiding therapeutics in certain tumour types due to availibility of drugs that target copy number aberrations (Ciriello et al., 2013). The OncoScanR FFPE Assay Kit has been optimised for whole genome copy number, loss of heterozygosity and somatic mutation detection from highly degraded FFPE samples. This technology is based on molecular inversion probe technology and the assay requires ≤ 80ng of input DNA and can utilise degraded DNA, with probes having a genomic footprint of just 40bp, making it ideally suited to FPPE samples. Our study provides deeper comparative insight into escape of primary glioblastoma form from treatment regime and how remaining cells evolved into recurrent glioblastoma. Citations: Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45(10):1127-33.

Materials/methods

OncoScan technology was used in comparative analysis in paired samples of primary and recurrent form of glioblastoma multiforme which supplements and extent our previous work based on cytogenetic characterization of this disease. Paired FFPE samples were gathered from cooperating hospitals, DNA was extracted by QIAmp DNA FFPE Tissue Kit and subsequently analysed according to OncoScan protocol.

Results and conclusions

Statistically analysed data that resulted in heatmaps will be presented and obtained data will be compared to recent literature.

Support: NT 13581; TE02000058.